Clinical data
Participant demographic information, past medical history,
comorbidities, inflammatory markers, high sensitivity (HS) troponin
levels, outpatient medications, and inpatient therapies were collected
from the electronic medical record. In addition, data on the need for
mechanical ventilation, duration of mechanical ventilation, intensive
care unit and hospital lengths of stay, and in-hospital mortality was
obtained. To standardize vasopressor dosing across participants
receiving different agents, the cumulativeĀ dose of norepinephrine
equivalents (NE Eq) was calculatedĀ as has been described
previously12, 13 with a conversion factor for
angiotensin II of 1 ng per 0.1 mcg of norepinephrine based upon the
ATHOS-3 trial (Supplement Table 1).13 All 12 lead
electrocardiograms (ECGs) recorded during admission were reviewed by a
board certified cardiologist to determine the development of atrial
arrhythmias. Participants with ECG documentation of a new-onset atrial
fibrillation, atrial flutter, or atrial tachycardia were labeled as
having an ATA.